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(decreased recurrence over several years). With tamoxifen as
comparator, anastrozole is a cost-effective adjuvant treatment for
postmenopausal HR+ EBC and lies within acceptable cost-effec-
tiveness benchmarks.
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OBJECTIVES: Five polychemotherapy regimens: gemcitabine-
cisplatine (GC), vinorelbine-cisplatine (VC), docetaxel-cisplatine
(DC), paclitaxel-cisplatine (PC) and paclitaxel-carboplatine
(PCa), are commonly used in ﬁrst-line treatment of advanced
non-small cell lung cancer. Whereas taxanes have to be admin-
istered within a conventional day-hospitalization setting, gemc-
itabine and vinorelbine can be administrated in a home-care
setting. The purpose of the study is to ﬁnd out which case man-
agement minimizes costs for the French National Health Insur-
ance while ensuring patient safety. METHODS: A Markov
model was constructed in order to estimate the cost conse-
quences of home administrations for gemcitabine and vinorel-
bine chemotherapies without cisplatine compared to taxanes
administrated only at hospitals. Transitional probabilities are
based on Scagliotti (2002), Fossela (2002), Smit (2003), pub-
lished randomized trials. In all cases, no differences in efﬁcacy
were found between regimens. A cost-minimization analysis was
performed. The costs of treatments were calculated by adding
DRG costs, onerous drug reimbursed over DRGs, and trans-
portation expenses. Costs of severe toxicities, diagnosis and pal-
liative care are taken into account. RESULTS: With the
conservative hypothesis of non-different therapeutic efﬁcacy and
no more than two administrations at home per cycle, GC and
VC appear with annual follow-up costs of €7315[7064–7570]
and €7686[7378–7997]. Administrated within a conventional
day-hospitalization, their annual follow-up costs are of 8103 
and €9605, respectively. Taxanes DC, PC and PCa at hospital
have annual follow-up costs of €8778[8185–9108],
€9068[8367–9446], and €10,140[9436–10,510]. To obtain the
same overall costs between GC and DC, the acquisition cost of
gemcitabine has to be multiplied by 50%. CONCLUSION:
According to the national guidelines on chemotherapy home care
infusion, the choice of extrahospital treatment in case of equiv-
alent efﬁcacy has a better efﬁciency from the French National
Health Insurance’s perspective.
